Blog
RSS FeedPosted by Michael Wonder on 29 May 2022
ATAGI update following weekly COVID-19 meeting (25 May 2022)
27 May 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 25 ...
Posted by Michael Wonder on 26 May 2022
COVID-19 vaccine weekly safety report (26 May 2022)
26 May 2022 - To 22 May 2022, the TGA has received 555 reports which have been assessed as likely to ...
Posted by Michael Wonder on 26 May 2022
Prescription medicines: applications under evaluation (May 2022)
26 May 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...
Posted by Michael Wonder on 26 May 2022
TGA approves new medicine for patients with Cushing's syndrome
26 May 2022 - Osilodrostat phosphate is a cortisol synthesis inhibitor. ...
Posted by Michael Wonder on 25 May 2022
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
25 May 2022 - The Australian Technical Advisory Group on Immunisation (ATAGI) have expanded their recommendations on the use of additional ...
Posted by Michael Wonder on 23 May 2022
ATAGI update following weekly COVID-19 meeting (18 May 2022)
23 May 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 18 ...
Posted by Michael Wonder on 19 May 2022
COVID-19 vaccine weekly safety report (19 May 2022)
19 May 2022 - To 15 May 2022, the TGA has received 555 reports which have been assessed as likely to ...
Posted by Michael Wonder on 16 May 2022
Pfizer settles two lawsuits, starts another over etanercept biosimilar in Australia
17 May 2022 - After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit ...
Posted by Michael Wonder on 13 May 2022
TGA commences evaluation of Moderna COVID-19 vaccine (Spikevax) for children aged 6 months to 5 years old
13 May 2022 - The TGA has received, and immediately commenced evaluation of, an application from Moderna to extend the ...
Posted by Michael Wonder on 13 May 2022
TGA removes age limit for BBIBP-CorV (Sinopharm) COVID-19 vaccine recognition for international travel to Australia
13 May 2022 - The TGA has determined that the BBIBP-CorV (Sinopharm) COVID-19 vaccine will be 'recognised' for all ages for ...
Posted by Michael Wonder on 12 May 2022
ATAGI update following weekly COVID-19 meeting (11 May 2022)
12 May 2022 - On Wednesday 11 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 12 May 2022
COVID-19 vaccine weekly safety report (12 May 2022)
12 May 2022 - To 8 May 2022, the TGA has received 554 reports which have been assessed as likely to ...
Posted by Michael Wonder on 11 May 2022
ATAGI update following weekly COVID-19 meeting (4 May 2022)
9 May 2022 - On Wednesday 4 May 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. ...
Posted by Michael Wonder on 09 May 2022
Product information update for COVID-19 treatment Xevudy (sotrovimab)
6 May 2022 - On 7 April 2022, the TGA announced receipt of an application from GSK for a higher (1000 ...
Posted by Michael Wonder on 05 May 2022
COVID-19 vaccine weekly safety report (5 May 2022)
5 May 2022 - To 1 May 2022, the TGA has received 546 reports which have been assessed as likely to ...